Blogs

Since joining the TechBio Boost programme, SokerData has refined its business model, adopted a more strategic approach to market entry, built new partnerships and is securing funding to accelerate R&D and commercialisation.

For this Q&A blog, BIA sat down with Annnelise Vuidepot, Chief Technology Officer at Immunocore, to find out about her journey with the company, from its inception to the present day.

This week I highlight innovation across the sector and call on pension funds to be mandated to support our industry.

In this blog, Priya Mande, CEO of RNAvate, tells her story of how she became a CEO and why the role is meaningful to her.

In a world of uncertainty, Britain’s biotech future looks strong.

In this blog, Maddie Cass, Senior Policy and Public Affairs Executive at BIA, explores a major milestone for agricultural innovation in England: the implementation of a clear, science-based regulatory pathway for precision-bred plants.

In this blog, Michelle Mitchell, CEO of Cancer Research UK, talks about West Streeting recent visit to the Bowelbabe Lab.

Sarah Brockbank, Strategy Leader – Complex Medicines at Medicines Discovery Catapult, shares insight into a new regulatory roadmap created by the UK’s Intracellular Drug Delivery Centre (IDDC).

Washington’s shifting policy landscape continues to cause uncertainty, while the UK is staying calm. Join our webinar this Thursday to hear how we’re engaging with international partners and government to ensure the UK voice is heard and our sector remains robust.

Amid ongoing geopolitical uncertainty, the UK life sciences ecosystem is keeping calm and carrying on.

In this blog, Dr Emma Lawrence, Head of data tech policy and public affairs at BIA, writes about the UK government's recent £600 million initiative to launch a Health Data Research Service which aims to revolutionize access to NHS data and tackle longstanding governance and technical hurdles.

Change is happening fast for our sector at the moment, and I expect to see big calls from the UK government as it responds to global events this week.

Andrew Merrison from FI Group shares his knowledge about the new rule changes HMRC has put in place concerning overseas costs about biotech.

Will James and Robyn Trigg from Osborne Clarke look at how the UPC's practice and procedure has developed since it began operations in June 2023.

President Trump’s “Liberation Day” announcement on April 2 could disrupt biotech, with BIO’s survey showing 90% of U.S. biotech firms relying on imports for FDA-approved products. In addition, news from the mRNA vaccine progress, new lab spaces and Innovate UK’s new leadership.

In this blog, BIA member Brainomix, following its series C round, answers questions on the company's origins and future trajectory.

It’s Spring Statement week and we have a webinar on what it means for the sector this Friday; also in this blog - why VPAG needs sorting and a new Series C raise for a BIA member, Brainomix.

Emerson partners with biopharmaceutical companies to drive innovation, efficiency, and compliance in life sciences manufacturing through cutting-edge automation and process expertise.

In this blog, BIA CEO Steve Bates OBE gives his take on the announcement that the UK government is consulting on introducing a new law to raise the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies' NHS sales revenues in the second half of 2025.

Following a number of ‘firsts’ for Stablepharma during 2024, we spoke with Ozgur Tuncer, CEO and Executive Director about a year that has accelerated the commercialisation of the world’s first fridge-free vaccine, SPVX02, for the prevention of Tetanus and Diphtheria.